Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18299415 | 0.98 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL12616560 | 0.84 | CHRNB2 (0.36) | BRD4EGFR | |
| SCHEMBL31397502 | 0.83 | SLC6A1 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL8577121 | 0.83 | MAPT (0.38) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL18299029 | 0.83 | MAPT (0.38) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL19910918 | 0.82 | SLC6A1 (0.35) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL19910919 | 0.82 | SLC6A1 (0.35) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL19910926 | 0.81 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL11713259 | 0.81 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL11079186 | 0.81 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-115785074-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016198908-A1 | ROR NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A1 2414/4885GABRA5 249/4885GABRB2 505/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A1 2414/4885GABRA5 249/4885GABRB2 505/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A1 2414/4885GABRA5 249/4885GABRB2 505/4885 |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A1 2414/4885GABRA5 249/4885GABRB2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.